• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
    • Why Immunogenicity Risk Assessment?
    • Why EpiVax?
  • About Us
    • Company History
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Report from the field: Overview of the Sixth Annual Vaccine Renaissance Conference

Report from the field: Overview of the Sixth Annual Vaccine Renaissance Conference

by Adam | Oct 22, 2016

Hum Vaccin Immunother. 2013 Jul;9(7):1555-7. doi: 10.4161/hv.24833. Epub 2013 May 31.
Low immunogenicity predicted for emerging avian-origin H7N9: Implication for influenza vaccine design

Low immunogenicity predicted for emerging avian-origin H7N9: Implication for influenza vaccine design

by Adam | Oct 22, 2016

Hum Vaccin Immunother. Volume 9, Issue 5 May 2013:950–956.

Making Vaccines “On Demand”: A Potential Solution for Emerging Pathogens and Biodefense?

by Adam | Oct 22, 2016

Human Vaccines and Immunotherapy. Sep 2013.
Immunization with Cross-conserved H1N1 Influenza CD4+ T Cell Epitopes Lowers Viral Burden in HLA DR3 Transgenic Mice

Immunization with Cross-conserved H1N1 Influenza CD4+ T Cell Epitopes Lowers Viral Burden in HLA DR3 Transgenic Mice

by Adam | Oct 22, 2016

Hum Vaccin Immunother. 2013 Sep 17;9(10).
Cross-conservation of T-cell epitopes: now even more relevant to (H7N9) influenza vaccine design

Cross-conservation of T-cell epitopes: now even more relevant to (H7N9) influenza vaccine design

by Adam | Oct 22, 2016

Hum Vaccin Immunother. 2014 Feb Full Text
« Older Entries
Next Entries »

Recent Posts

  • EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services    
  • Replacing Animal Models with Human-Relevant New Approach Methodologies (NAMs) for Immunogenicity in Clinic
  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy

Recent Comments

  1. Homepage on Doing Well and Giving Back in December

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.